Key Highlights

  • Second-quarter Revenue reached $257.5 million, up 6.6% year over year, with adjusted EBITDA of $155.8 million at a 60.5% margin.
  • Free Cash Flow rose to $54.6 million from $36.6 million a year earlier, though the company still posted a net loss of $59.2 million.
  • Bookings exceeded $70 million through the first half, on track toward a $100 million full-year target implying roughly 50% growth.
  • Claritev raised full-year 2026 revenue guidance to $1.0–$1.02 billion and adjusted EBITDA guidance to $610–$620 million, and shares jumped on the news.

Claritev (NYSE:CTEV), the healthcare technology and data-analytics company formerly known as MultiPlan, jumped as a year-long transformation program showed fresh signs of traction. With revenue rising, bookings accelerating and guidance raised, investors are responding to signs that the company is breaking out even as it continues to post net losses and carries substantial debt.

Claritev provides services that help payers, employers and providers manage the cost and transparency of medical care, serving a vast network that includes hundreds of payers, tens of thousands of employers and more than a million providers. The company is working to broaden its offerings into new vertical markets and to embed AI across its operations and products as part of its turnaround.

Latest Developments

In its second-quarter 2026 results, Claritev reported revenue of $257.5 million, up 6.6% year over year, with adjusted EBITDA of $155.8 million (a 60.5% margin) and free cash flow of $54.6 million, up from $36.6 million a year earlier. The company still posted a net loss of $59.2 million, though narrower than the prior year. Bookings exceeded $70 million through the first half, on track toward a $100 million full-year target that would represent roughly 50% growth, including seven-figure deals in the third-party-administrator market. Claritev raised full-year 2026 revenue guidance to $1.0–$1.02 billion and adjusted EBITDA guidance to $610–$620 million.

Financial and Business Position

Claritev generates strong adjusted EBITDA margins and healthy free cash flow, but it carries significant Debt and continues to report net losses, so its transformation is ultimately about converting operational improvements and bookings growth into sustainable profitability and deleveraging. The accelerating bookings, expansion into new verticals and AI initiatives are the pillars management is counting on to reignite growth. Raising guidance is an encouraging signal that the turnaround is gaining traction, though the company's Leverage remains a central consideration.

Stock-Market Context

The stock carries a favorable analyst rating, consistent with a market responding to evidence that the transformation is taking hold. The breakout case rests on continued bookings growth, expansion into new markets, AI-driven product wins and progress toward profitability and debt reduction; the cautionary case is that a heavily indebted company still posting net losses must demonstrate durable growth before the market sustains its re-rating, and that healthcare cost-management faces its own competitive and regulatory pressures.

What Investors Should Watch

Investors may focus on whether bookings reach the $100 million full-year target, continued revenue growth and Margin durability, progress narrowing net losses and reducing leverage, and traction in new vertical markets and AI-enabled offerings. Evidence that the transformation is converting strong cash flow and accelerating bookings into a clear path toward profitability would do the most to confirm that Claritev's breakout has legs.

A Turnaround Bet Still in Progress

Claritev's transformation is a bet that a company built around healthcare cost management can reinvent itself as a growth-oriented data-and-technology business, and the early evidence is mixed but encouraging. On the positive side, accelerating bookings, expansion into new verticals such as the third-party-administrator market, and a raised guidance suggest the commercial engine is gaining traction, while the company's strong adjusted-EBITDA margins and improving free cash flow give it the means to invest.

The overhang is the balance sheet: like many companies that emerged from private-equity ownership, Claritev carries substantial debt, and until it converts its operating strength into net profitability and meaningful deleveraging, the Equity will remain sensitive to its capital structure. The AI initiatives management is emphasizing could either be a genuine differentiator in healthcare Data Analytics or a buzzword that must still prove its commercial value. For investors, the coming quarters are about whether bookings growth and margin durability translate into a credible path toward profitability and lower leverage.